SINYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
SHOULDER INNOVATIONS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.25+0.16 (+0.88%)
Close on Oct 19, 2026
- Market cap
- $378.43M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
39.8%
8M of 21M shares
Institutional holders
72
24 new, 9 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
7 buys · 17 sales
Net sold $5.25M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 3,848,791 | 19.00% | 13G (passive) | Aug 29, 2025 |
| Abigail P. Johnson | 3,673,960 | 17.70% | 13G (passive) amendment | Jun 30, 2026 |
| Casey M. Tansey | 2,740,787 | 13.30% | 13G (passive) | Sep 30, 2025 |
| Martemanshurk B.V. | 2,212,207 | 10.70% | 13D (active) amendment | Aug 5, 2026 |
| Henry A. Plain Jr. | 1,885,136 | 9.30% | 13G (passive) | Sep 30, 2025 |
| Churchill R. Sean | 1,363,394 | 6.70% | 13G (passive) | Sep 30, 2025 |
| Arboretum Investment Manager VI, LLC | 1,163,891 | 5.80% | 13G (passive) | Aug 1, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 3,673,960 | 17.65% | $74.51M | −110,592 | 0.00% |
| BlackRock, Inc. | 638,420 | 3.07% | $12.95M | +82,368 | 0.00% |
| Sectoral Asset Management Inc | 430,407 | 2.07% | $8.73M | – | 6.09% |
| Vanguard Capital Management LLC | 392,181 | 1.88% | $7.95M | −21,299 | 0.00% |
| KCM Capital Inc | 300,000 | 1.44% | $6.08M | +265,000 | 0.98% |
| TimesSquare Capital Management, LLC | 298,219 | 1.43% | $6.05M | −24,545 | 88.95% |
| Roubaix Capital, LLC | 255,288 | 1.23% | $5.18M | −1,833 | 1.86% |
| Driehaus Capital Management LLC | 253,760 | 1.22% | $5.15M | New | 0.03% |
| Parkman Healthcare Partners LLC | 226,212 | 1.09% | $4.59M | New | 0.47% |
| Geode Capital Management, LLC | 199,529 | 0.96% | $4.05M | +15,850 | 0.00% |
| CM Management, LLC | 145,000 | 0.70% | $2.94M | +45,000 | 1.96% |
| JPMorgan Chase & Co | 124,437 | 0.60% | $2.62M | −6,274 | 0.00% |
| Morgan Stanley | 117,265 | 0.56% | $2.38M | −40,313 | 0.00% |
| State Street Corp | 114,859 | 0.55% | $2.33M | +21,614 | 0.00% |
| HighTower Advisors, LLC | 102,640 | 0.49% | $2.08M | New | 0.00% |
| Jane Street Group, LLC | 86,307 | 0.41% | $1.75M | New | 0.00% |
| Walleye Capital LLC | 86,155 | 0.41% | $1.75M | +972 | 0.01% |
| Schonfeld Strategic Advisors LLC | 77,737 | 0.37% | $1.58M | New | 0.01% |
| Northern Trust Corp | 71,291 | 0.34% | $1.45M | +7,224 | 0.00% |
| Vanguard Portfolio Management LLC | 70,335 | 0.34% | $1.43M | +9,338 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 8M | 39.8% | 24 / 30 | 11 / 9 | 2M | 1M |
| Q1 2026 | 58 | 8M | 36.6% | 16 / 24 | 9 / 7 | 2M | 0M |
| Q4 2025 | 50 | 7M | 31.8% | 13 / 12 | 16 / 5 | 1M | 1M |
| Q3 2025 | 42 | 7M | 35.2% | 42 / 0 | 0 / 0 | 7M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Medical Technology and Devices Portfolio | 947,763 | 4.55% | $13.93M | 0.47% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 777,617 | 3.74% | $17.68M | 0.20% | Jul 31, 2026 |
| Select Health Care Portfolio | 545,286 | 2.62% | $8.02M | 0.14% | May 31, 2026 |
| Fidelity Balanced Fund | 505,572 | 2.43% | $7.43M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 387,903 | 1.86% | $8.82M | 0.19% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 322,231 | 1.55% | $6.53M | 0.00% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 310,692 | 1.49% | $7.07M | 0.23% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 264,648 | 1.27% | $5.37M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 114,700 | 0.55% | $2.61M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 87,838 | 0.42% | $1.78M | 0.01% | Jun 30, 2026 |
| JPMorgan Small Cap Value Fund | 76,733 | 0.37% | $1.56M | 0.12% | Jun 30, 2026 |
| VIP Balanced Portfolio | 68,600 | 0.33% | $1.39M | 0.02% | Jun 30, 2026 |
| AST Small-Cap Equity Portfolio | 66,815 | 0.32% | $1.36M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 56,418 | 0.27% | $1.14M | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 53,226 | 0.26% | $782.42K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Joseph Ball | CEO & Executive Chairman, Director | 390,999 | 1.88% | Sep 14, 2026 |
| Matthew Fraser Ahearn | Chief Operating Officer, Director | 245,776 | 1.18% | Aug 18, 2026 |
| Jonathan E. Osborne | Chief Commercial Officer | 60,355 | 0.29% | Aug 10, 2026 |
| Jeffrey S. Points | Chief Financial Officer | 68,835 | 0.33% | Mar 17, 2026 |
| David Lawrence Blue | See Remarks | 139,372 | 0.67% | Feb 3, 2026 |
| Kevin K. Sidow | Director | 25,056 | 0.12% | Jun 29, 2026 |
| Casey M. Tansey | Director, 10% owner | 2,745,831 | 13.19% | Jun 29, 2026 |
| Paul Buckman | Director | 63,750 | 0.31% | Jun 29, 2026 |
| Richard Buchholz | Director | 18,712 | 0.09% | Jun 29, 2026 |
| Andrew Hykes | Director | 6,769 | 0.03% | Jun 29, 2026 |
| Michael A. Carusi | Director | 1,626,136 | 7.81% | Aug 5, 2025 |
| Geoffrey B. Pardo | Director, 10% owner | 2,288,148 | 10.99% | Aug 5, 2025 |
| Healthcare Holding B.V. Gilde | 10% owner | 2,185,914 | 10.50% | Aug 28, 2026 |
| Jean George | – | – | – | Aug 5, 2025 |
| LSV Associates II, LLC | – | – | – | Aug 5, 2025 |
| Lightstone Ventures II, L.P. | – | – | – | Aug 5, 2025 |
| Henry A. Plain JR | – | – | – | Aug 5, 2025 |
| Lightstone Ventures II (A), L.P. | – | 1,885,136 | 9.05% | Aug 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Joseph Ball CEO & Executive Chairman, Director | Sep 14, 2026 | Option exercise | +89,233 | $2.10 | $187.39K | 390,999 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Sep 14, 2026 | Sale | −10,175 | $18.45 | $187.73K | 380,824 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 26, 2026 | Sale | −1,196 | $22.60 | $27.03K | 2,185,914 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 24, 2026 | Sale | −681 | $22.62 | $15.40K | 2,187,110 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 21, 2026 | Sale | −20,516 | $22.61 | $463.87K | 2,187,791 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 20, 2026 | Sale | −3,900 | $22.60 | $88.14K | 2,208,307 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −12,586 | $20.94 | $263.55K | 245,776 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −1,600 | $21.38 | $34.21K | 244,176 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −8,314 | $20.10 | $167.11K | 258,362 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Aug 14, 2026 | Gift | −2,500 | – | – | 266,676 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 6, 2026 | Sale | −2,095 | $22.60 | $47.35K | 2,212,207 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 5, 2026 | Sale | −7,338 | $22.64 | $166.13K | 2,214,302 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 4, 2026 | Sale | −99,812 | $22.77 | $2.27M | 2,221,640 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 3, 2026 | Sale | −10,751 | $22.71 | $244.16K | 2,321,452 |
| Healthcare Holding B.V. Gilde 10% owner | Jul 31, 2026 | Sale | −20,034 | $22.73 | $455.37K | 2,332,203 |
| Healthcare Holding B.V. Gilde 10% owner | Jul 30, 2026 | Sale | −28,245 | $23.36 | $659.80K | 2,352,237 |
| Richard Buchholz Director | Jun 26, 2026 | Award | +5,046 | – | – | 18,712 |
| Kevin K. Sidow Director | Jun 26, 2026 | Award | +5,046 | – | – | 25,056 |
| Andrew Hykes Director | Jun 26, 2026 | Award | +5,046 | – | – | 6,769 |
| Casey M. Tansey Director, 10% owner | Jun 26, 2026 | Award | +5,046 | – | – | 52,712 |
| Paul Buckman Director | Jun 26, 2026 | Award | +5,046 | – | – | 63,750 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Jun 15, 2026 | Sale(10b5-1 plan) | −2,500 | $19.26 | $48.15K | 269,176 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Jun 15, 2026 | Sale(10b5-1 plan) | −1,644 | $18.20 | $29.92K | 271,676 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Jun 12, 2026 | Sale(10b5-1 plan) | −15,856 | $18.68 | $296.19K | 273,320 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Apr 30, 2026 | Option exercise | +10,000 | $2.48 | $24.80K | 300,018 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Apr 20, 2026 | Option exercise | +14,243 | $2.86 | $40.73K | 286,765 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Apr 20, 2026 | Option exercise | +7,421 | $2.48 | $18.40K | 272,522 |
| Paul Buckman Director | Mar 13, 2026 | Option exercise | +26,205 | $2.10 | $55.03K | 65,710 |
| Paul Buckman Director | Mar 13, 2026 | Option exercise | +19,401 | $2.48 | $48.11K | 39,505 |
| Paul Buckman Director | Mar 13, 2026 | Tax withholding | −3,292 | $14.62 | $48.13K | 62,418 |
| Paul Buckman Director | Mar 13, 2026 | Tax withholding | −3,714 | $14.82 | $55.04K | 58,704 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Mar 13, 2026 | Buy | +2,200 | $15.18 | $33.40K | 278,866 |
| Jeffrey S. Points Chief Financial Officer | Mar 13, 2026 | Option exercise | +13,264 | $2.48 | $32.89K | 68,785 |
| Jeffrey S. Points Chief Financial Officer | Mar 13, 2026 | Buy | +2,000 | $15.00 | $30.00K | 70,785 |
| Richard Buchholz Director | Mar 13, 2026 | Buy | +1,000 | $14.84 | $14.84K | 13,666 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Feb 6, 2026 | Option exercise | +10,000 | $2.48 | $24.80K | 274,604 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Feb 6, 2026 | Option exercise | +2,062 | $2.10 | $4.33K | 276,666 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Dec 31, 2025 | Award | +477 | $12.16 | $5.80K | 215,856 |
| David Lawrence Blue See Remarks | Dec 31, 2025 | Award | +1,041 | $12.16 | $12.66K | 139,372 |
| Jeffrey S. Points Chief Financial Officer | Dec 31, 2025 | Award | +1,076 | $12.16 | $13.08K | 55,521 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Dec 31, 2025 | Award | +1,661 | $12.16 | $20.20K | 120,118 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Dec 12, 2025 | Buy | +3,900 | $14.89 | $58.07K | 118,457 |
| Jeffrey S. Points Chief Financial Officer | Dec 12, 2025 | Buy | +1,005 | $14.98 | $15.05K | 54,445 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Dec 11, 2025 | Buy | +3,300 | $14.83 | $48.94K | 114,557 |
| Jeffrey S. Points Chief Financial Officer | Dec 11, 2025 | Buy | +995 | $14.65 | $14.58K | 53,440 |
| Robert Joseph Ball CEO & EXECUTIVE CHAIRMAN, Director | Sep 12, 2025 | Buy | +6,000 | $15.49 | $92.94K | 111,259 |
| Jeffrey S. Points CHIEF FINANCIAL OFFICER | Sep 12, 2025 | Buy | +1,600 | $15.67 | $25.07K | 52,445 |
| David Lawrence Blue SEE REMARKS | Sep 12, 2025 | Option exercise | +78,616 | $2.10 | $165.09K | 122,553 |
| David Lawrence Blue SEE REMARKS | Sep 12, 2025 | Option exercise | +15,778 | $2.48 | $39.13K | 138,331 |
| Robert Joseph Ball CEO & EXECUTIVE CHAIRMAN, Director | Sep 11, 2025 | Buy | +2,000 | $14.90 | $29.80K | 105,259 |
| Jeffrey S. Points CHIEF FINANCIAL OFFICER | Sep 11, 2025 | Option exercise | +13,264 | $2.48 | $32.89K | 50,845 |
| Matthew Fraser Ahearn CHIEF OPERATING OFFICER, Director | Sep 11, 2025 | Option exercise | +12,286 | $0.93 | $11.43K | 120,320 |
| Matthew Fraser Ahearn CHIEF OPERATING OFFICER, Director | Sep 11, 2025 | Option exercise | +16,443 | $2.48 | $40.78K | 215,379 |
| Matthew Fraser Ahearn CHIEF OPERATING OFFICER, Director | Sep 11, 2025 | Option exercise | +78,616 | $2.10 | $165.09K | 198,936 |
| Michael A. Carusi Director | Aug 1, 2025 | Conversion | +1,618,470 | – | – | 1,618,470 |
| Michael A. Carusi Director | Aug 1, 2025 | Buy | +266,666 | $15.00 | $4.00M | 1,885,136 |
| Michael A. Carusi Director | Aug 1, 2025 | Award | +7,666 | – | – | 7,666 |
| Richard Buchholz Director | Aug 1, 2025 | Buy | +5,000 | $15.00 | $75.00K | 12,666 |
| Richard Buchholz Director | Aug 1, 2025 | Award | +7,666 | – | – | 7,666 |
| Geoffrey B. Pardo Director, 10% owner | Aug 1, 2025 | Conversion | +2,280,482 | – | – | 2,280,482 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ball Robert Officer, Director | Sep 14, 2026 | 10,175 | $187.71K | Sep 14, 2026 | Private Acquisition from Issuer/Affiliate |
| Ahearn Matthew Director, Officer | Aug 17, 2026 | 22,500 | $466.43K | Aug 17, 2026 | Preferred Equity Financing |
| Healthcare Holding B.V.; Cooperatieve Gilde Healthcare V. U.A. Gilde 10% Stockholder | Jul 29, 2026 | 200,000 | $4.85M | Jul 29, 2026 | Private placement of Series D convertible preferred stock; converted into common stock upon IPO closing 08/01/2025. Holding period tacks under Rule 144(d)(3)(ii). |
| Ahearn Matthew Director, Officer | Jun 12, 2026 | 20,000 | $375.20K | Jun 12, 2026 | Preferred Equity Financing |